Aim: FOLFIRINOX has proven effective in advanced PDAC. In order to overcome toxicity issues, dose/schedule modifications and additional supportive measures are being considered. Methods: We reviewed the clinical charts of 270 PDAC pts receiving classic FOLFIRINOX (group 1) or mFOLFIRINOX (group 2) at 7 Italian Institutions.
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Results: Patient characteristics are shown in the table. Fifty seven pts/590 cycles and 213 pts/1127 cycles were available for analysis in groups 1 and 2, respectively. Overall toxicity was mild; significant differences in G2-4 toxicities between the two groups: asthenia (10% vs 6%, p = 0.001), diarrhea (7% vs 4%, p = 0.01), and thrombocytopenia (4% vs 0.5%, p < 0.00001), favouring group 2, and neutropenia (5% vs 12%, p < 0.0001), favouring group 1. G-CSF was used more frequently in group 1 (80% vs 36%, p < 0.0001). Dose delays were comparable between the two groups; dose reductions were more common in group 2 (39% vs 28%, p < 0.00001). No differences in the complete control of nausea/vomiting at cycle 1 (no N/V) with or without aprepitant were observed (50% vs 45%, respectively). The presence of a biliary stent did not appear to significantly worsen toxicity. ORR and disease control rate (DCR: PR + SD) were 39% and 61%, respectively, without significant differences between the two groups. Median PFS was 7 mos in both groups. Median OS, however, was significantly longer in group 2 (18 vs 12 mos, respectively; p = 0.04), mostly due to a better performance of mFOLFIRINOX in PS0 pts. Conclusions: FOLFIRINOX/mFOLFIRINOX are well tolerated and easily manageable on an outpatient basis and can be safely used in pts carrying biliary stents. Differences in toxicity and efficacy with modified schedules deserve further investigation. Disclosure: All authors have declared no conflicts of interest.
